Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function

Phase 2

Recruiting

• Conditions: Graft-versus-host Disease; Poor Graft Function; Low Donor T-cell Chimerism
• Interventions: Biological: Mesenchymal stem cells

• Registration Number: NCT00603330
• Lead Sponsor: University of Liege

Brief Summary

The present project aims at investigating the role of MSC for the treatment of patients with

Part 1: Steroid-refractory grade II-IV acute GVHD.

Part 2: Poor graft function (PGF)

Part 3: Low or falling donor T-cell chimerism after allogeneic HCT.

This is a multicenter phase II study examining the feasibility and efficacy of this approach.

Detailed Description

Part 1: complete recruitment Part 2: complete recruitment Part 3: recruiting

Study Timeline

• Study Start: 2008-01
• Study First Submitted: 2008-01-16
• Study First Submitted QC: 2008-01-28
• Study First Posted: 2008-01-29
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-08
• Last Update Posted: 2024-05-09
• Primary Completion: 2024-08
• Study Completion: 2024-08

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Patient eligibility criteria

1. Male or female of any age.
2. Previous allogeneic transplantation (related or unrelated donor, any degree of HLA matching) or autologous transplantation (for part 2 only) of HSC at any time before.
3. Any source of HSC (marrow, PBSC, cord blood) and any conditioning regimen.
4. Informed consent given by donor or his/her guardian if of minor age.
5. Additional criteria for each part of the protocol:

Part 1: MSC for steroid-refractory grade II-IV acute GVHD

1. Allogeneic transplantation.

2. Grade II-IV acute GVHD (see appendix A for acute GVHD grading) de novo or following DLI.

3. Acute GVHD refractory to mPDN 2 mg/kg/day or equivalent, defined as

   • progression of GVHD on day 3 after initiation of steroids
   • no improvement of GVHD on day 7 after initiation of steroids
   • absence of complete resolution of acute GVHD on day 14 after initiation of steroids
   • relapse of acute GVHD during or after steroid taper.

4. Ongoing therapy with Ciclosporine or Tacrolimus at therapeutic doses.

5. Patient may have received previously any other form of treatment for acute GVHD, but no new treatment started within 1 month of study entry.

Part 2: MSC for poor graft function (PGF)

1. Allogeneic or autologous transplantation.

2. Cytopenia in 2 or 3 lineages:

   • Hb < 8.0 g/dL and reticulocytes < 1%, with or without transfusion
   • Plt < 20,000/µL without transfusion
   • Neutrophils < 500/µL, without G-CSF administration

   OR severe cytopenia in 1 lineage:

   • RBC transfusion dependent (if autologous transplantation; despite EPO administration if allogeneic transplantation)
   • Plt transfusion dependent
   • Neutrophils < 500/µL despite G-CSF administration

3. Cytopenia duration ≥ 2 weeks beyond day 28 after autologous HCT, or day 42 (day 60 for cord blood transplantation) after allogeneic HCT.

4. Cytopenia is not related to CMV or other infection, myelosuppressive/toxic drugs, renal failure, peripheral cell destruction or other identifiable cause.

5. In case of HLA-identical related donor and full donor chimerism, patient can only be included if a boost of donor CD34+ cells has been unsuccessful or is not feasible.

Part 3: MSC + DLI for poor donor T-cell chimerism

1. Nonmyeloablative allogeneic transplantation.

2. Donor T-cell chimerism < 50% for at least 2 consecutive weeks beyond day 21 after HCT OR

   • 20% decrease in donor T-cell chimerism with the second value < 50%.

MSC donor inclusion criteria

1. Related to the recipient (sibling, parent or child) or unrelated.
2. Male or female.
3. Age > 16 yrs (no age limit if same as HSC donor).
4. No HLA matching required.
5. Fulfills generally accepted criteria for allogeneic HSC donation.
6. Informed consent given by donor or his/her guardian if of minor age.

Exclusion Criteria

Patient exclusion criteria

1. HIV positive.
2. Active uncontrolled infection at time of scheduled MSC infusion.
3. Relapsing or progressing malignancy.

MSC donor exclusion criteria

1. HIV positive
2. Known allergy to Lidocaine
3. If donor other than HSC donor : any risk factor for transmissible infectious diseases.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
3	Mesenchymal stem cells	MSC + DLI for poor donor T-cell chimerism after allogeneic HCT. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
1	Mesenchymal stem cells	MSC infusion for steroid-refractory grade II-IV acute GVHD. In this arm, 4 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
2	Mesenchymal stem cells	MSC infusion for poor graft function. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.

Primary Outcome Measures

Name	Time	Method
Arm 2. Efficacy of MSC infusion as treatment for poor graft function	180 days
Arm 1. Efficacy of MSC infusion as treatment for steroid-resistant grade II - IV acute GVHD.	30 days
Arm 3. Efficacy of MSC infusion followed by donor lymphocyte infusion for preventing graft rejection in patients with low or failing donor T-cell chimerism after allogeneic HCT	180 days

Secondary Outcome Measures

Name	Time	Method
Toxicity of MSC infusion	180 days

Trial Locations

Locations (12)

AZ St Jan; 🇧🇪 Brugge, West Flanders, Belgium

AZ VUB Jette; 🇧🇪 Brussels, Brabant, Belgium

AZ Gasthuisberg Leuven; 🇧🇪 Leuven, Flamish Brabant, Belgium

UZ Gent; 🇧🇪 Gent, Flanders Ost, Belgium

Cliniques Universitaires Mont-Godinne; 🇧🇪 Yvoir, Namur, Belgium

Cliniques universitaires Saint-Luc- Université Catholique de Louvain; 🇧🇪 Brussels, Brabant, Belgium

Hôpital de Jolimont; 🇧🇪 Haine St Paul, Hainaut, Belgium

Hôpital Stuyvenberg; 🇧🇪 Antwerpen, Belgium

CHU Sart Tilman; 🇧🇪 Liege, Belgium

UZA; 🇧🇪 Edeghem, Antwerpen, Belgium

Hôpital des enfants Reine Fabiola; 🇧🇪 Brussels, Brabant, Belgium

University Hospital Maastricht; 🇳🇱 Maastricht, Limburg, Netherlands